New cocktail approach aims to wipe out High-Risk rectal cancer without surgery
NCT ID NCT06908031
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 2 trial tests a powerful mix of short-course radiation, chemotherapy (mFOLFOX6), an immunotherapy (PD-1 antibody), and a targeted drug (cetuximab or bevacizumab, depending on genetic markers) in people with high-risk rectal cancer that is mismatch repair proficient (pMMR) and microsatellite stable (MSS). The goal is to see if this combination can make the tumor disappear completely (pathological complete response). The study enrolls 49 adults aged 18-75 with tumors within 10 cm of the anal verge.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Short-course radiotherapy, mFOLFOX6 chemotherapy, PD-1 antibody, cetuximab (for RAS/BRAF wild-type), bevacizumab (for RAS/BRAF mutant)
What this could lead to
If successful, this combination could offer a more effective, non-surgical treatment path for high-risk rectal cancer, potentially increasing the chance of a complete response.
What could go wrong
This is an early-phase trial with only 49 participants, so results may not apply to all patients. Combining multiple therapies raises the risk of severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510065, China
Contact Phone: •••-•••-•••• Email: •••••@•••••